HK Stock Market Move | MICROPORT (00853) rose by over 5%. Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd.'s annual net profit attributable to shareholders increased by 12.17% year-on-year. The company's research products are steadily advancing.

MICROPORT (00853) rose by more than 5%, as of the time of this report, it has increased by 5.19%, to 1.42 Hong Kong dollars, with a turnover of 19.4691 million Hong Kong dollars. On the news front, recently, MICROPORT announced the preliminary results for the fiscal year 2025 for Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd., with total operating income of approximately 1.351 billion yuan, an increase of 11.96% year-on-year; net profit attributable to the parent company's owner of approximately 563 million yuan, an increase of 12.17% year-on-year; and basic earnings per share of 4.65 yuan. During the reporting period, the company's overseas sales revenue exceeded 250 million yuan, an increase of over 55% year-on-year, accounting for over 18% of the company's revenue. The company continues to promote cooperation with industry-leading customers globally and regionally, and continues to promote the market access and promotion of aortic and peripheral intervention products in Europe, Latin America, and the Asia-Pacific region. The company's research products are steadily advancing with a rich pipeline, including the registration submission of the Aegis II abdominal aortic stent graft system; the Hector thoracic multi-branch stent graft system has entered the domestic pre-market multi-center clinical stage, and has entered the national innovation 'green channel' during the reporting period, and has been commercialized through a customized approach in the European Union. At the same time, the product's Breakthrough Device Designation application has been submitted to the FDA in the United States; the thoracic and abdominal aortic stent graft system (customized) has obtained domestic filing certification; and the iliac artery branch stent graft system is about to enter the clinical trial initiation stage.